drug index
TRANSCRIPT
Lung Cancer 80 Suppl. 1 (2013) S67
Lung Cancer
journa l homepage: www.e lsev ier .com/ locate / lungcan
Contents lists available at SciVerse ScienceDirect
Drug index
Afatinib, S30 (65O)
Bevacizumab, S11 (26PD), S37 (85P)
Carboplatin, S20 (47P), S25 (55P), S31 (67O), S36 (81P), S55(125P)
Cisplatin, S25 (55P), S27 (60P), S28 (63P), S31 (67O), S36 (82P),S37 (84P, 85P), S38 (86P), S40 (93P)
Crizotinib, S2 (3P), S13 (31P)
Dacomitinib, S39 (92P)Docetaxel, S28 (63P), S32 (71PD), S37 (85P), S39 (90P), S40 (93P)
EGFR-TKI, S12 (27P), S30 (65O), S32 (71PD), S33 (73P), S35 (77P),S39 (91P)
Enobosarm, S32 (70PD)Erlotinib, S30 (65O), S32 (71PD), S33 (73P), S35 (79P), S39 (90P,
91P)Etoposide, S25 (55P), S36 (81P), S49 (115P)
Foretinib, S11 (26PD)
Gefitinib, S12 (27P), S30 (65O), S31 (68O), S32 (71PD), S36 (81P),S39 (91P, 92P)
Gemcitabine, S20 (47P), S37 (84P), S40 (93P)
Lanreotide, S20 (47P)
Paclitaxel, S25 (55P), S36 (81P)Pemetrexed, S34 (75P, 76P)
Tyrosine kinase inhibitors, S2 (5P), S12 (27P), S32 (69O), S33(73P)
Vintafolide, S16 (36O)
Zoledronic acid, S39 (91P)
*Page numbers for abstracts are followed by the abstract number(s) in parentheses.